Sandrine Sander, MD, PhD
Phone: +49 6221 56 5931

Modeling B-cell lymphomagenesis...


in the mouse – from bench to bedside.

Adaptive Immunity and Lymphoma


Our group has:

  • Established a pre-clinical mouse model of human Burkitt lymphoma (Sander et al. Cancer Cell 2012)
  • Identified the PI3K signaling pathway as synergistic factor in MYC-driven lymphomagenesis and new druggable target in Burkitt lymphoma (Sander et al. Cancer Cell 2012)
  • Characterized the function of the transcription factor FOXO1 during germinal center development (Sander et al. Immunity 2015)
  • Sander S, Calado DP, Srinivasan L, Köchert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, Bullinger L, Rajewsky K. Synergy between PI3K signalling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012, 22(2):167-79.
  • Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, Kühn R. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol. 2015, 33(5):543-8.
  • Sander S, Chu VT, Yasuda T, Franklin A, Graf R, Calado DP, Li S, Imami K, Selbach M, Di Virgilio M, Bullinger L, Rajewsky K. PI3 Kinase and FOXO1 transcription factor activity differentially control B cells in the germinal center light and dark zones. Immunity 2015,43(6):1075-86.
  • Deutsche Krebshilfe
  • Else Kröner-Fresenius-Stiftung